PDMR Shareholding/Share Incentive Plan
Updated : 07:00
31 December 2021
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company has been notified that on 29 December 2021, Yorkshire Building Society and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Stefan Macdonald, Susanne Munksted and Damian Thornton (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.
Enquiries:
Diaceutics PLC |
|
Philip White, Chief Financial Officer | Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Kieran Breheny |
|
Matthew Young |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stefan Macdonald | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Global Growth Officer and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
102.90 p | 146 | ||||||
Matched share award: | |||||||
Price(s) | Volume(s) | ||||||
102.90 p | 292 | ||||||
e. | Date of the transaction | Share purchase and Matched Share award: 29 December 2021 | |||||
f. | Place of the transaction | Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Managing Director and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
103.50 p | 200 | ||||||
Conditional share award: | |||||||
Price(s) | Volume(s) | ||||||
Nil | 400 | ||||||
e. | Date of the transaction | Share purchase and Conditional share award: 29 December 2021 | |||||
f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Damian Thornton | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Operating Officer and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
103.50 p | 143 | ||||||
Options: | |||||||
Price(s) | Volume(s) | ||||||
Nil | 286 | ||||||
| |||||||
e. | Date of the transaction | Share purchase and Option award: 29 December 2021 | |||||
f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Option award: Off-Market | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.